Novel thienopyrimidinones as mGluR1 antagonists.

There has been much attention to discover mGluR1 antagonists for treating various central nervous system diseases such as seizures and neuropathic pain. Thienopyrimidinone derivatives were designed, synthesized, and biologically evaluated against mGluR1. Among the synthesized compounds, 3-(4-methoxyphenyl)-7-(o-tolyl)thienopyrimidin-4-one 30 exhibited the most potent inhibitory activity with an IC50 value of 45 nM and good selectivity over mGluR5. Also, the selective mGluR1 antagonist 30 showed marginal hERG channel activity (IC50 = 9.87 µM), good profiles to CYP isozymes, and a good pharmacokinetic profile. Overall, the compound 30 was identified as a selective mGluR1 antagonist with a good pharmacokinetic profile, which is probably devoid of cardiac side effect and drug-drug interactions. Therefore, the compound 30 can be expected to be broadly used as mGluR1 antagonistic chemical probe in in vitro and in vivo study for investigating CNS diseases.

Novel pyrimidoazepine analogs as serotonin 5-HT(2A) and 5-HT(2C) receptor ligands for the treatment of obesity.

Obesity is one of the most serious public health problems worldwide in the 21st century. Current therapeutic treatment for obesity is mostly focused on preventive measures involving dietary control and physical exercises in combination with anti-obesity medications. However, most of these anti-obesity medications have little or no effect on weight loss, and some cases have demonstrated fatal side effects. Due to the urgent need for highly potent and selective anti-obesity agents, the serotonin receptors (5-HTR) have been the focus of much interest as a novel therapeutic target. In this report, we have developed pyrimidoazepine analogs targeting the 5-HT2A and 5-HT2C receptors and evaluated their biological activity in vitro and in vivo as novel anti-obesity agents. We were able to identify 6p as the most potent 5-HT2A and 5-HT2C ligand in vitro (IC50 = 3 nM and 2.3 nM, respectively), and this compound also demonstrated the greatest potency in vivo. In an acute obesity model, mice treated with 6p showed significant decrease in body weight gain and food intake over approximately 77-94% compared to a control group. In a chronic obesity model, mice treated with 6p also showed a marked decrease in food intake and body weight gain.

Synthesis and evaluation of oxime derivatives as modulators for amyloid beta-induced mitochondrial dysfunction.

Starting from quinuclidinyl oxime 1 identified by preliminary screening, a series of azacycles-containing oxime derivatives was synthesized. Their mPTP blocking activities were evaluated by a JC-1 assay, measuring the change of mitochondrial membrane potential. The inhibitory activity of nine compounds against amyloid beta-induced mPTP opening was comparable or even superior to that of piracetam. Among them, 12d effectively maintained mitochondrial function and cell viabilities on the ATP assay, the MTT assay, and the ROS assay. In addition, it exhibited favorable in vitro stability and pharmacokinetic characteristics, which hold a promise for further development of AD therapeutics.

Network analysis of hepatic genes responded to high-fat diet in C57BL/6J mice: nutrigenomics data mining from recent research findings.

Obesity and its associated complications, including diabetes, dyslipidemia, atherosclerosis, and some cancers, have been a global health problem with a rapid increase of the obese population. In this study, we selected 31 obesity candidate genes in the liver of high-fat-induced obese C57BL/6J mice through investigation of literature search and analyzed functional protein-protein interaction of the genes using the STRING database. Most of the obesity candidate genes were closely connected through lipid metabolism, and in particular acyl-coenzyme A oxidase 1 appeared to be a core obesity gene. Overall, genes involved in fatty acid beta-oxidation, fatty acid synthesis, and gluconeogenesis were up-regulated, and genes involved in sterol biosynthesis, insulin signaling, and oxidative stress defense system were down-regulated with a high-fat diet. Future identification of core obesity genes and their functional targets is expected to provide a new way to prevent obesity by phytochemicals or functional foods on the basis of food and nutritional genomics.

Antioxidant and antithrombus activities of enzyme-treated Salicornia herbacea extracts.

This study was attempted to investigate antioxidant and antithrombus activities of water and methanol extracts of enzyme-treated Salicornia herbacea (SH)by in vitro assays observing the inhibitory activity of a rat liver microsomal lipid peroxidation, DPPH radical scavenging activity, activated partial thromboplastin times (APTT) and thromboplastin times (TT). The water and methanol extracts from enzyme-treated SH inhibited the lipid peroxidation in a dose-dependent manner over a concentration range of 0.1-1.0 mg/ml. The activity of enzyme-treated water and methanol extracts was stronger than that of non-enzyme-treated water and methanol extracts. The inhibitory activity of the water extract was higher at a concentration of 1.0 mg/ml than that of the methanol extract. The activity was the highest in the enzyme-treated water extract, and was approximately 1.08 times higher than alpha-tocopherol, a natural antioxidant. The DPPH radical scavenging activities of the SH extracts were similar to their lipid peroxidation inhibitory activity. The APTT of the water and methanol extracts was delayed at a concentration range of 0.25-2.0 mg/ml in a dose-dependent manner. The APTT of the methanol extract was longer at a concentration of 1.0 mg/ml than that of the water extracts. The enzyme-treated methanol extract exhibited the longest APTT even at a concentration of 0.50 mg/ml. The TT activities of the SH extracts were also similar to their APTT activities. These results suggest that water and methanol extracts of the enzyme-treated SH may be useful as potential antioxidant and antithrombus sources, respectively.